CN112739422B - Cd200r激动剂抗体及其用途 - Google Patents

Cd200r激动剂抗体及其用途 Download PDF

Info

Publication number
CN112739422B
CN112739422B CN201980060272.1A CN201980060272A CN112739422B CN 112739422 B CN112739422 B CN 112739422B CN 201980060272 A CN201980060272 A CN 201980060272A CN 112739422 B CN112739422 B CN 112739422B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
cd200r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980060272.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112739422A (zh
Inventor
S·J·德马雷斯特
A·科斯特
P·梅塔
S·C·波特
D·I·鲁伊斯
D·R·威彻
吴秀凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202410652453.6A priority Critical patent/CN118530360A/zh
Publication of CN112739422A publication Critical patent/CN112739422A/zh
Application granted granted Critical
Publication of CN112739422B publication Critical patent/CN112739422B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980060272.1A 2018-09-14 2019-09-11 Cd200r激动剂抗体及其用途 Active CN112739422B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410652453.6A CN118530360A (zh) 2018-09-14 2019-09-11 Cd200r激动剂抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14
US62/731,204 2018-09-14
PCT/US2019/050511 WO2020055943A1 (en) 2018-09-14 2019-09-11 Cd200r agonist antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410652453.6A Division CN118530360A (zh) 2018-09-14 2019-09-11 Cd200r激动剂抗体及其用途

Publications (2)

Publication Number Publication Date
CN112739422A CN112739422A (zh) 2021-04-30
CN112739422B true CN112739422B (zh) 2024-05-28

Family

ID=68051977

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980060272.1A Active CN112739422B (zh) 2018-09-14 2019-09-11 Cd200r激动剂抗体及其用途
CN202410652453.6A Withdrawn CN118530360A (zh) 2018-09-14 2019-09-11 Cd200r激动剂抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410652453.6A Withdrawn CN118530360A (zh) 2018-09-14 2019-09-11 Cd200r激动剂抗体及其用途

Country Status (27)

Country Link
US (2) US11319370B2 (https=)
EP (1) EP3849667A1 (https=)
JP (3) JP7185051B2 (https=)
KR (1) KR102705378B1 (https=)
CN (2) CN112739422B (https=)
AR (1) AR116668A1 (https=)
AU (1) AU2019339334B2 (https=)
BR (1) BR112021003254A2 (https=)
CA (1) CA3112763C (https=)
CL (1) CL2021000606A1 (https=)
CO (1) CO2021003093A2 (https=)
CR (1) CR20210134A (https=)
DO (1) DOP2021000040A (https=)
EA (1) EA202190530A1 (https=)
EC (1) ECSP21017619A (https=)
IL (1) IL281442B2 (https=)
JO (1) JOP20210048B1 (https=)
MA (1) MA53604A (https=)
MX (1) MX2021003026A (https=)
MY (1) MY196156A (https=)
NZ (1) NZ773626A (https=)
PE (1) PE20211742A1 (https=)
PH (1) PH12021550530A1 (https=)
SG (1) SG11202101697YA (https=)
TW (1) TWI749367B (https=)
WO (1) WO2020055943A1 (https=)
ZA (2) ZA202101246B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN116323665A (zh) 2020-05-29 2023-06-23 23和我公司 抗cd200r1抗体及其使用方法
PE20251170A1 (es) * 2022-04-06 2025-04-23 Mirobio Ltd Anticuerpos cd200r disenados por ingenieria y usos de estos
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法
AU2024282979A1 (en) 2023-06-02 2026-01-22 Aimed Bio Inc. Anti-cd200r1 antibody and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679519A (zh) * 2006-12-22 2010-03-24 先灵公司 Cd200r的抗体
CN102906115A (zh) * 2010-01-11 2013-01-30 阿雷克森制药公司 在经抗cd200抗体治疗的人体内的免疫调节效应的生物标记
CN102918062A (zh) * 2010-02-11 2013-02-06 阿雷克森制药公司 使用抗cd200抗体的治疗方法
CN103690947A (zh) * 2006-01-12 2014-04-02 阿莱克申药物公司 抗ox-2/cd200的抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103690947A (zh) * 2006-01-12 2014-04-02 阿莱克申药物公司 抗ox-2/cd200的抗体及其用途
CN101679519A (zh) * 2006-12-22 2010-03-24 先灵公司 Cd200r的抗体
CN102906115A (zh) * 2010-01-11 2013-01-30 阿雷克森制药公司 在经抗cd200抗体治疗的人体内的免疫调节效应的生物标记
CN102918062A (zh) * 2010-02-11 2013-02-06 阿雷克森制药公司 使用抗cd200抗体的治疗方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Monoclonal Antibody-Mediated CD200 Receptor Signaling Suppresses Macrophage Activation and Tissue Damage in Experimental Autoimmune Uveoretinitis;David A. Copland et al.;The American Journal of Pathology;全文 *

Also Published As

Publication number Publication date
CO2021003093A2 (es) 2021-03-19
ECSP21017619A (es) 2021-04-29
JP7490025B2 (ja) 2024-05-24
NZ773626A (en) 2024-11-29
CA3112763A1 (en) 2020-03-19
EP3849667A1 (en) 2021-07-21
IL281442A (en) 2021-04-29
DOP2021000040A (es) 2021-03-31
SG11202101697YA (en) 2021-04-29
US11319370B2 (en) 2022-05-03
KR102705378B1 (ko) 2024-09-12
MY196156A (en) 2023-03-17
TW202024132A (zh) 2020-07-01
TWI749367B (zh) 2021-12-11
ZA202101246B (en) 2023-04-26
JOP20210048A1 (ar) 2021-03-11
CN118530360A (zh) 2024-08-23
AU2019339334B2 (en) 2023-03-09
JP2022500080A (ja) 2022-01-04
CR20210134A (es) 2021-03-29
MA53604A (fr) 2021-12-22
US20200087395A1 (en) 2020-03-19
ZA202204978B (en) 2022-09-28
WO2020055943A1 (en) 2020-03-19
AR116668A1 (es) 2021-06-02
BR112021003254A2 (pt) 2021-05-18
EA202190530A1 (ru) 2021-06-21
IL281442B1 (en) 2023-11-01
JP7185051B2 (ja) 2022-12-06
PE20211742A1 (es) 2021-09-06
KR20210044262A (ko) 2021-04-22
CL2021000606A1 (es) 2021-09-20
PH12021550530A1 (en) 2022-02-14
IL281442B2 (en) 2024-03-01
MX2021003026A (es) 2021-05-27
CA3112763C (en) 2024-05-14
JOP20210048B1 (ar) 2024-12-22
JP2022141959A (ja) 2022-09-29
CN112739422A (zh) 2021-04-30
AU2019339334A1 (en) 2021-03-18
US20220251198A1 (en) 2022-08-11
JP2024105529A (ja) 2024-08-06

Similar Documents

Publication Publication Date Title
CN111886253B (zh) Pd-1激动剂抗体及其用途
JP6833798B2 (ja) 抗ｌａｇ−３結合タンパク質
CN112566935B (zh) 抗ox40抗体和使用方法
CN112739422B (zh) Cd200r激动剂抗体及其用途
CN110156892B (zh) 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN106554417B (zh) 抗ox40抗体和使用其的方法
CN103946238B (zh) 抗ox40抗体及使用其的方法
JP7072622B2 (ja) Ｂｔｌａアゴニスト抗体およびその使用
WO2017031242A1 (en) Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
CN110662768A (zh) 治疗性抗cd40配体抗体
TW202146451A (zh) 抗人類cd19抗體
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
CN114728063B (zh) 用抗ox40抗体和多重激酶抑制剂治疗癌症
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
EA048233B1 (ru) Агонистические антитела к cd200r и их применение
HK40005909B (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant